Henry Whitfield is a psychotherapy trainer and psychedelic therapy researcher, having collected years of data through psychedelic retreats that explored new ways of combining psychotherapy processes with psilocybin. He is an Association of Contextual Behavioural Science (ACBS) Peer-reviewed Acceptance and Commitment Therapy trainer, an Accredited Advanced TIR (PTSD therapy) Trainer and Cognitive Behavioural Psychotherapist (MSc – CBT), and Visiting Researcher at Regent’s University – School of Psychotherapy and Psychology. 

For over seven years Henry ran and supervised brief therapy for PTSD projects for Victim Support and Mind in London gun crime hot spots, using CBT and TIR. Henry has also trained over 1500 psychological therapists since 2003, supervising mental health professionals in the NHS for ACT and Trauma work. He lead the development of new ways to learn ACT skills efficiently, offering one of the first ACT skills programs ever in 2007. He is also a passionate integral thinker, publishing journal articles and book chapters on the integration of therapeutic models including, REBT-mindfulness, ACT-TIR-CBT, Person-centred-TIR. His psychedelic plant medicine path and ACT leanings helped him to work on collapsing the polarities that divide our field such as 'psychodynamic' vs 'cognitive-behavioural'. He has written, co-written and edited training manuals for ACT, TIR and FAP (relational psychodynamic). Now he focuses his research on understanding pathways to lasting psychotherapeutic change through all phases of psychedelic therapy.  He is also author of a new model of psychological flexibility A Spectrum of Selves, tailored to a psychedelic therapy context published 2021 in Frontiers in Psychiatry.

Robert Krause DNP APRN-BC is the founder and Director of Clinical Services at Centered PLLC in New Haven, CT. His work involves clinical practice, education and research. He has been in practice for 27 years currently treating adults with a wide range of presentations from those with seriously and persistently mental illness, trauma, depression, and comorbid diagnosis to couples and families.

As an educator Dr Krause has been faculty at the Yale’s Schools of Medicine and Nursing, Quinnipiac University, Western Connecticut State University, and The Graduate Institute. He has also precepted graduate students in psychiatric nursing, and in professional counseling. He is currently a faculty member on a massive online course called “Addiction Treatment: Clinical Skills for Healthcare Providers” that has enrolled 62,000 students to date. He has facilitated or co-facilitates trainings for Ketamine Assisted Therapy including assisting Dr Phil Wolfson in a Ketamine training earlier this year. He has also contributed to the development of the Expanded ACT training for psychedelic therapy with Henry Whitfield. Additionally, he has supervised therapists for ketamine assisted therapy and has supervised therapists providing psychedelic therapy using psilocybin analogs for the Embark program of Cybin pharmaceuticals.

Dr. Krause has been trained in and utilizes a number of different therapeutic modalities including Trauma therapy (certificate from Harvard University), Acceptance and Commitment Therapy (ACT), Trauma Incident Reduction (TIR), Sex therapy (certificate from CIIS) and Psychedelic therapy ( from CIIS), Ketamine Assisted Therapy (Ketamine Training Center). He is a MAPS therapist.

Dr Krause was a co-author of Yale’s Manual for Psilocybin Assisted Therapy and was a therapist with the Psilocybin induced neuroplasticity in the treatment of Major Depressive Disorder at the Yale School of Medicine. Among publications he has co-authored are:

(2020). Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame. Journal of Contextual Behavioral Science, 15, 12-19.

(2021) Ketamine-assisted psychotherapy for PTSD related to racial discrimination. Clinical Case Studies.

(2024) Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial. Sci Rep 14, 8833

Larry Leeman MD MPH is a Professor in Family and Community Medicine; Obstetrics and Gynecology at the University of New Mexico School of Medicine and board certified in Addiction Medicine. He graduated from the California Institute of Integral Studies Program in Psychedelic Assisted Therapies and Research in 2021, has been certified in MDMA Assisted Therapy by MAPS and has trained in Ketamine Assisted Psychotherapy with PRATI and Polaris.
During a research sabbatical at the University of Wisconsin he participated in research with MDMA and Psilocybin. His current research focus in psychedelic assisted therapies at the University of New Mexico focuses on trauma and addiction, group psychedelic assisted therapy, and the use of MDMA for postpartum women with PTSD and opioid use disorder. He is currently completing his second year of training in Hakomi, a form of mindfulness certified Somatic psychotherapy and is in the Grof Holotropic Breathwork practitioner training program.